nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—CYP3A7—Tamoxifen—pancreatic cancer	0.0467	0.0745	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0467	0.0745	CbGbCtD
Aprepitant—CYP3A7—Irinotecan—pancreatic cancer	0.0359	0.0572	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0359	0.0572	CbGbCtD
Aprepitant—CYP3A5—Tamoxifen—pancreatic cancer	0.0351	0.0559	CbGbCtD
Aprepitant—CYP1A2—Dacarbazine—pancreatic cancer	0.0328	0.0523	CbGbCtD
Aprepitant—CYP3A5—Erlotinib—pancreatic cancer	0.0298	0.0475	CbGbCtD
Aprepitant—CYP2C19—Tamoxifen—pancreatic cancer	0.0283	0.0451	CbGbCtD
Aprepitant—CYP3A5—Irinotecan—pancreatic cancer	0.0269	0.0429	CbGbCtD
Aprepitant—CYP3A7—Docetaxel—pancreatic cancer	0.0263	0.0419	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.0263	0.0419	CbGbCtD
Aprepitant—CYP3A7—Sunitinib—pancreatic cancer	0.0262	0.0417	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.0262	0.0417	CbGbCtD
Aprepitant—CYP1A2—Tamoxifen—pancreatic cancer	0.0261	0.0416	CbGbCtD
Aprepitant—CYP2C9—Tamoxifen—pancreatic cancer	0.0235	0.0375	CbGbCtD
Aprepitant—CYP1A2—Erlotinib—pancreatic cancer	0.0222	0.0353	CbGbCtD
Aprepitant—CYP3A5—Docetaxel—pancreatic cancer	0.0197	0.0314	CbGbCtD
Aprepitant—CYP3A5—Sunitinib—pancreatic cancer	0.0196	0.0313	CbGbCtD
Aprepitant—CYP1A2—Fluorouracil—pancreatic cancer	0.0192	0.0306	CbGbCtD
Aprepitant—CYP2C9—Fluorouracil—pancreatic cancer	0.0173	0.0276	CbGbCtD
Aprepitant—CYP3A4—Tamoxifen—pancreatic cancer	0.0137	0.0218	CbGbCtD
Aprepitant—CYP3A4—Erlotinib—pancreatic cancer	0.0116	0.0185	CbGbCtD
Aprepitant—CYP3A4—Irinotecan—pancreatic cancer	0.0105	0.0167	CbGbCtD
Aprepitant—CYP3A4—Docetaxel—pancreatic cancer	0.00769	0.0123	CbGbCtD
Aprepitant—CYP3A4—Sunitinib—pancreatic cancer	0.00766	0.0122	CbGbCtD
Aprepitant—CYP3A4—Doxorubicin—pancreatic cancer	0.00573	0.00914	CbGbCtD
Aprepitant—Convulsion—Docetaxel—pancreatic cancer	0.000119	0.000475	CcSEcCtD
Aprepitant—Hypertension—Docetaxel—pancreatic cancer	0.000119	0.000473	CcSEcCtD
Aprepitant—Infestation NOS—Epirubicin—pancreatic cancer	0.000118	0.000473	CcSEcCtD
Aprepitant—Infestation—Epirubicin—pancreatic cancer	0.000118	0.000473	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000117	0.000469	CcSEcCtD
Aprepitant—Chest pain—Docetaxel—pancreatic cancer	0.000117	0.000467	CcSEcCtD
Aprepitant—Arthralgia—Docetaxel—pancreatic cancer	0.000117	0.000467	CcSEcCtD
Aprepitant—Myalgia—Docetaxel—pancreatic cancer	0.000117	0.000467	CcSEcCtD
Aprepitant—Nausea—Sunitinib—pancreatic cancer	0.000117	0.000467	CcSEcCtD
Aprepitant—Renal failure—Epirubicin—pancreatic cancer	0.000116	0.000465	CcSEcCtD
Aprepitant—Asthenia—Irinotecan—pancreatic cancer	0.000116	0.000465	CcSEcCtD
Aprepitant—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000116	0.000464	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000116	0.000464	CcSEcCtD
Aprepitant—Stomatitis—Epirubicin—pancreatic cancer	0.000115	0.000461	CcSEcCtD
Aprepitant—Conjunctivitis—Epirubicin—pancreatic cancer	0.000115	0.00046	CcSEcCtD
Aprepitant—Urinary tract infection—Epirubicin—pancreatic cancer	0.000115	0.00046	CcSEcCtD
Aprepitant—Neutropenia—Doxorubicin—pancreatic cancer	0.000115	0.000459	CcSEcCtD
Aprepitant—Dysuria—Doxorubicin—pancreatic cancer	0.000115	0.000459	CcSEcCtD
Aprepitant—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000114	0.000457	CcSEcCtD
Aprepitant—Dry mouth—Docetaxel—pancreatic cancer	0.000114	0.000457	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000114	0.000457	CcSEcCtD
Aprepitant—Pollakiuria—Doxorubicin—pancreatic cancer	0.000114	0.000454	CcSEcCtD
Aprepitant—Asthenia—Gemcitabine—pancreatic cancer	0.000113	0.000452	CcSEcCtD
Aprepitant—Haematuria—Epirubicin—pancreatic cancer	0.000113	0.000451	CcSEcCtD
Aprepitant—Confusional state—Docetaxel—pancreatic cancer	0.000113	0.000451	CcSEcCtD
Aprepitant—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000112	0.000448	CcSEcCtD
Aprepitant—Oedema—Docetaxel—pancreatic cancer	0.000112	0.000448	CcSEcCtD
Aprepitant—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000112	0.000448	CcSEcCtD
Aprepitant—Weight increased—Doxorubicin—pancreatic cancer	0.000112	0.000447	CcSEcCtD
Aprepitant—Pruritus—Gemcitabine—pancreatic cancer	0.000112	0.000446	CcSEcCtD
Aprepitant—Infection—Docetaxel—pancreatic cancer	0.000111	0.000445	CcSEcCtD
Aprepitant—Weight decreased—Doxorubicin—pancreatic cancer	0.000111	0.000444	CcSEcCtD
Aprepitant—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000111	0.000443	CcSEcCtD
Aprepitant—Diarrhoea—Irinotecan—pancreatic cancer	0.000111	0.000443	CcSEcCtD
Aprepitant—Pneumonia—Doxorubicin—pancreatic cancer	0.00011	0.00044	CcSEcCtD
Aprepitant—Shock—Docetaxel—pancreatic cancer	0.00011	0.00044	CcSEcCtD
Aprepitant—Nervous system disorder—Docetaxel—pancreatic cancer	0.00011	0.000439	CcSEcCtD
Aprepitant—Pruritus—Fluorouracil—pancreatic cancer	0.00011	0.000439	CcSEcCtD
Aprepitant—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00011	0.000438	CcSEcCtD
Aprepitant—Infestation NOS—Doxorubicin—pancreatic cancer	0.00011	0.000438	CcSEcCtD
Aprepitant—Infestation—Doxorubicin—pancreatic cancer	0.00011	0.000438	CcSEcCtD
Aprepitant—Tachycardia—Docetaxel—pancreatic cancer	0.000109	0.000437	CcSEcCtD
Aprepitant—Skin disorder—Docetaxel—pancreatic cancer	0.000109	0.000435	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000109	0.000434	CcSEcCtD
Aprepitant—Bradycardia—Epirubicin—pancreatic cancer	0.000108	0.000433	CcSEcCtD
Aprepitant—Diarrhoea—Gemcitabine—pancreatic cancer	0.000108	0.000432	CcSEcCtD
Aprepitant—Renal failure—Doxorubicin—pancreatic cancer	0.000108	0.000431	CcSEcCtD
Aprepitant—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000107	0.000429	CcSEcCtD
Aprepitant—Dizziness—Irinotecan—pancreatic cancer	0.000107	0.000428	CcSEcCtD
Aprepitant—Stomatitis—Doxorubicin—pancreatic cancer	0.000107	0.000427	CcSEcCtD
Aprepitant—Anorexia—Docetaxel—pancreatic cancer	0.000107	0.000427	CcSEcCtD
Aprepitant—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000107	0.000426	CcSEcCtD
Aprepitant—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000107	0.000426	CcSEcCtD
Aprepitant—Diarrhoea—Fluorouracil—pancreatic cancer	0.000106	0.000424	CcSEcCtD
Aprepitant—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000106	0.000423	CcSEcCtD
Aprepitant—Pharyngitis—Epirubicin—pancreatic cancer	0.000106	0.000422	CcSEcCtD
Aprepitant—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000105	0.00042	CcSEcCtD
Aprepitant—Hypotension—Docetaxel—pancreatic cancer	0.000105	0.000418	CcSEcCtD
Aprepitant—Haematuria—Doxorubicin—pancreatic cancer	0.000105	0.000418	CcSEcCtD
Aprepitant—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000105	0.000418	CcSEcCtD
Aprepitant—Urethral disorder—Epirubicin—pancreatic cancer	0.000104	0.000417	CcSEcCtD
Aprepitant—Vomiting—Irinotecan—pancreatic cancer	0.000103	0.000412	CcSEcCtD
Aprepitant—Dizziness—Fluorouracil—pancreatic cancer	0.000103	0.00041	CcSEcCtD
Aprepitant—Rash—Irinotecan—pancreatic cancer	0.000102	0.000408	CcSEcCtD
Aprepitant—Dermatitis—Irinotecan—pancreatic cancer	0.000102	0.000408	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000102	0.000408	CcSEcCtD
Aprepitant—Headache—Irinotecan—pancreatic cancer	0.000102	0.000406	CcSEcCtD
Aprepitant—Insomnia—Docetaxel—pancreatic cancer	0.000101	0.000405	CcSEcCtD
Aprepitant—Paraesthesia—Docetaxel—pancreatic cancer	0.000101	0.000402	CcSEcCtD
Aprepitant—Erythema multiforme—Epirubicin—pancreatic cancer	0.000101	0.000402	CcSEcCtD
Aprepitant—Vomiting—Gemcitabine—pancreatic cancer	0.0001	0.000401	CcSEcCtD
Aprepitant—Bradycardia—Doxorubicin—pancreatic cancer	0.0001	0.0004	CcSEcCtD
Aprepitant—Dyspnoea—Docetaxel—pancreatic cancer	9.99e-05	0.000399	CcSEcCtD
Aprepitant—Somnolence—Docetaxel—pancreatic cancer	9.96e-05	0.000398	CcSEcCtD
Aprepitant—Rash—Gemcitabine—pancreatic cancer	9.95e-05	0.000398	CcSEcCtD
Aprepitant—Dermatitis—Gemcitabine—pancreatic cancer	9.95e-05	0.000397	CcSEcCtD
Aprepitant—Eye disorder—Epirubicin—pancreatic cancer	9.94e-05	0.000397	CcSEcCtD
Aprepitant—Tinnitus—Epirubicin—pancreatic cancer	9.92e-05	0.000396	CcSEcCtD
Aprepitant—Headache—Gemcitabine—pancreatic cancer	9.89e-05	0.000395	CcSEcCtD
Aprepitant—Cardiac disorder—Epirubicin—pancreatic cancer	9.87e-05	0.000394	CcSEcCtD
Aprepitant—Flushing—Epirubicin—pancreatic cancer	9.87e-05	0.000394	CcSEcCtD
Aprepitant—Vomiting—Fluorouracil—pancreatic cancer	9.87e-05	0.000394	CcSEcCtD
Aprepitant—Dyspepsia—Docetaxel—pancreatic cancer	9.86e-05	0.000394	CcSEcCtD
Aprepitant—Hypoaesthesia—Doxorubicin—pancreatic cancer	9.79e-05	0.000391	CcSEcCtD
Aprepitant—Rash—Fluorouracil—pancreatic cancer	9.79e-05	0.000391	CcSEcCtD
Aprepitant—Dermatitis—Fluorouracil—pancreatic cancer	9.78e-05	0.000391	CcSEcCtD
Aprepitant—Pharyngitis—Doxorubicin—pancreatic cancer	9.77e-05	0.00039	CcSEcCtD
Aprepitant—Decreased appetite—Docetaxel—pancreatic cancer	9.74e-05	0.000389	CcSEcCtD
Aprepitant—Headache—Fluorouracil—pancreatic cancer	9.72e-05	0.000388	CcSEcCtD
Aprepitant—Urinary tract disorder—Doxorubicin—pancreatic cancer	9.72e-05	0.000388	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Docetaxel—pancreatic cancer	9.67e-05	0.000386	CcSEcCtD
Aprepitant—Connective tissue disorder—Doxorubicin—pancreatic cancer	9.67e-05	0.000386	CcSEcCtD
Aprepitant—Fatigue—Docetaxel—pancreatic cancer	9.66e-05	0.000386	CcSEcCtD
Aprepitant—Angiopathy—Epirubicin—pancreatic cancer	9.65e-05	0.000386	CcSEcCtD
Aprepitant—Urethral disorder—Doxorubicin—pancreatic cancer	9.65e-05	0.000385	CcSEcCtD
Aprepitant—Nausea—Irinotecan—pancreatic cancer	9.63e-05	0.000385	CcSEcCtD
Aprepitant—Immune system disorder—Epirubicin—pancreatic cancer	9.61e-05	0.000384	CcSEcCtD
Aprepitant—Mediastinal disorder—Epirubicin—pancreatic cancer	9.59e-05	0.000383	CcSEcCtD
Aprepitant—Constipation—Docetaxel—pancreatic cancer	9.58e-05	0.000383	CcSEcCtD
Aprepitant—Pain—Docetaxel—pancreatic cancer	9.58e-05	0.000383	CcSEcCtD
Aprepitant—Chills—Epirubicin—pancreatic cancer	9.54e-05	0.000381	CcSEcCtD
Aprepitant—Alopecia—Epirubicin—pancreatic cancer	9.4e-05	0.000375	CcSEcCtD
Aprepitant—Nausea—Gemcitabine—pancreatic cancer	9.38e-05	0.000375	CcSEcCtD
Aprepitant—Mental disorder—Epirubicin—pancreatic cancer	9.32e-05	0.000372	CcSEcCtD
Aprepitant—Erythema multiforme—Doxorubicin—pancreatic cancer	9.31e-05	0.000372	CcSEcCtD
Aprepitant—Erythema—Epirubicin—pancreatic cancer	9.26e-05	0.00037	CcSEcCtD
Aprepitant—Malnutrition—Epirubicin—pancreatic cancer	9.26e-05	0.00037	CcSEcCtD
Aprepitant—Feeling abnormal—Docetaxel—pancreatic cancer	9.23e-05	0.000369	CcSEcCtD
Aprepitant—Nausea—Fluorouracil—pancreatic cancer	9.22e-05	0.000368	CcSEcCtD
Aprepitant—Eye disorder—Doxorubicin—pancreatic cancer	9.2e-05	0.000367	CcSEcCtD
Aprepitant—Tinnitus—Doxorubicin—pancreatic cancer	9.18e-05	0.000367	CcSEcCtD
Aprepitant—Gastrointestinal pain—Docetaxel—pancreatic cancer	9.16e-05	0.000366	CcSEcCtD
Aprepitant—Flushing—Doxorubicin—pancreatic cancer	9.13e-05	0.000365	CcSEcCtD
Aprepitant—Cardiac disorder—Doxorubicin—pancreatic cancer	9.13e-05	0.000365	CcSEcCtD
Aprepitant—Flatulence—Epirubicin—pancreatic cancer	9.12e-05	0.000364	CcSEcCtD
Aprepitant—Dysgeusia—Epirubicin—pancreatic cancer	9.07e-05	0.000362	CcSEcCtD
Aprepitant—Back pain—Epirubicin—pancreatic cancer	8.96e-05	0.000358	CcSEcCtD
Aprepitant—Angiopathy—Doxorubicin—pancreatic cancer	8.93e-05	0.000357	CcSEcCtD
Aprepitant—Muscle spasms—Epirubicin—pancreatic cancer	8.9e-05	0.000356	CcSEcCtD
Aprepitant—Immune system disorder—Doxorubicin—pancreatic cancer	8.89e-05	0.000355	CcSEcCtD
Aprepitant—Mediastinal disorder—Doxorubicin—pancreatic cancer	8.87e-05	0.000354	CcSEcCtD
Aprepitant—Body temperature increased—Docetaxel—pancreatic cancer	8.86e-05	0.000354	CcSEcCtD
Aprepitant—Abdominal pain—Docetaxel—pancreatic cancer	8.86e-05	0.000354	CcSEcCtD
Aprepitant—Chills—Doxorubicin—pancreatic cancer	8.83e-05	0.000353	CcSEcCtD
Aprepitant—Alopecia—Doxorubicin—pancreatic cancer	8.7e-05	0.000347	CcSEcCtD
Aprepitant—Mental disorder—Doxorubicin—pancreatic cancer	8.62e-05	0.000344	CcSEcCtD
Aprepitant—Ill-defined disorder—Epirubicin—pancreatic cancer	8.59e-05	0.000343	CcSEcCtD
Aprepitant—Erythema—Doxorubicin—pancreatic cancer	8.57e-05	0.000342	CcSEcCtD
Aprepitant—Malnutrition—Doxorubicin—pancreatic cancer	8.57e-05	0.000342	CcSEcCtD
Aprepitant—Anaemia—Epirubicin—pancreatic cancer	8.56e-05	0.000342	CcSEcCtD
Aprepitant—Flatulence—Doxorubicin—pancreatic cancer	8.44e-05	0.000337	CcSEcCtD
Aprepitant—Dysgeusia—Doxorubicin—pancreatic cancer	8.39e-05	0.000335	CcSEcCtD
Aprepitant—Malaise—Epirubicin—pancreatic cancer	8.35e-05	0.000334	CcSEcCtD
Aprepitant—Syncope—Epirubicin—pancreatic cancer	8.3e-05	0.000332	CcSEcCtD
Aprepitant—Back pain—Doxorubicin—pancreatic cancer	8.29e-05	0.000331	CcSEcCtD
Aprepitant—Hypersensitivity—Docetaxel—pancreatic cancer	8.25e-05	0.00033	CcSEcCtD
Aprepitant—Muscle spasms—Doxorubicin—pancreatic cancer	8.24e-05	0.000329	CcSEcCtD
Aprepitant—Palpitations—Epirubicin—pancreatic cancer	8.18e-05	0.000327	CcSEcCtD
Aprepitant—Loss of consciousness—Epirubicin—pancreatic cancer	8.14e-05	0.000325	CcSEcCtD
Aprepitant—Cough—Epirubicin—pancreatic cancer	8.08e-05	0.000323	CcSEcCtD
Aprepitant—Asthenia—Docetaxel—pancreatic cancer	8.04e-05	0.000321	CcSEcCtD
Aprepitant—Convulsion—Epirubicin—pancreatic cancer	8.02e-05	0.00032	CcSEcCtD
Aprepitant—Hypertension—Epirubicin—pancreatic cancer	7.99e-05	0.000319	CcSEcCtD
Aprepitant—Ill-defined disorder—Doxorubicin—pancreatic cancer	7.95e-05	0.000318	CcSEcCtD
Aprepitant—Pruritus—Docetaxel—pancreatic cancer	7.93e-05	0.000317	CcSEcCtD
Aprepitant—Anaemia—Doxorubicin—pancreatic cancer	7.92e-05	0.000316	CcSEcCtD
Aprepitant—Myalgia—Epirubicin—pancreatic cancer	7.88e-05	0.000315	CcSEcCtD
Aprepitant—Chest pain—Epirubicin—pancreatic cancer	7.88e-05	0.000315	CcSEcCtD
Aprepitant—Arthralgia—Epirubicin—pancreatic cancer	7.88e-05	0.000315	CcSEcCtD
Aprepitant—Anxiety—Epirubicin—pancreatic cancer	7.86e-05	0.000314	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	7.83e-05	0.000313	CcSEcCtD
Aprepitant—Discomfort—Epirubicin—pancreatic cancer	7.79e-05	0.000311	CcSEcCtD
Aprepitant—Malaise—Doxorubicin—pancreatic cancer	7.73e-05	0.000309	CcSEcCtD
Aprepitant—Dry mouth—Epirubicin—pancreatic cancer	7.71e-05	0.000308	CcSEcCtD
Aprepitant—Syncope—Doxorubicin—pancreatic cancer	7.68e-05	0.000307	CcSEcCtD
Aprepitant—Diarrhoea—Docetaxel—pancreatic cancer	7.67e-05	0.000306	CcSEcCtD
Aprepitant—Confusional state—Epirubicin—pancreatic cancer	7.62e-05	0.000304	CcSEcCtD
Aprepitant—Palpitations—Doxorubicin—pancreatic cancer	7.57e-05	0.000302	CcSEcCtD
Aprepitant—Anaphylactic shock—Epirubicin—pancreatic cancer	7.56e-05	0.000302	CcSEcCtD
Aprepitant—Oedema—Epirubicin—pancreatic cancer	7.56e-05	0.000302	CcSEcCtD
Aprepitant—Loss of consciousness—Doxorubicin—pancreatic cancer	7.53e-05	0.000301	CcSEcCtD
Aprepitant—Infection—Epirubicin—pancreatic cancer	7.51e-05	0.0003	CcSEcCtD
Aprepitant—Cough—Doxorubicin—pancreatic cancer	7.48e-05	0.000299	CcSEcCtD
Aprepitant—Shock—Epirubicin—pancreatic cancer	7.43e-05	0.000297	CcSEcCtD
Aprepitant—Convulsion—Doxorubicin—pancreatic cancer	7.42e-05	0.000297	CcSEcCtD
Aprepitant—Nervous system disorder—Epirubicin—pancreatic cancer	7.41e-05	0.000296	CcSEcCtD
Aprepitant—Dizziness—Docetaxel—pancreatic cancer	7.41e-05	0.000296	CcSEcCtD
Aprepitant—Thrombocytopenia—Epirubicin—pancreatic cancer	7.4e-05	0.000296	CcSEcCtD
Aprepitant—Hypertension—Doxorubicin—pancreatic cancer	7.4e-05	0.000295	CcSEcCtD
Aprepitant—Tachycardia—Epirubicin—pancreatic cancer	7.38e-05	0.000295	CcSEcCtD
Aprepitant—Skin disorder—Epirubicin—pancreatic cancer	7.34e-05	0.000293	CcSEcCtD
Aprepitant—Hyperhidrosis—Epirubicin—pancreatic cancer	7.31e-05	0.000292	CcSEcCtD
Aprepitant—Myalgia—Doxorubicin—pancreatic cancer	7.29e-05	0.000291	CcSEcCtD
Aprepitant—Chest pain—Doxorubicin—pancreatic cancer	7.29e-05	0.000291	CcSEcCtD
Aprepitant—Arthralgia—Doxorubicin—pancreatic cancer	7.29e-05	0.000291	CcSEcCtD
Aprepitant—Anxiety—Doxorubicin—pancreatic cancer	7.27e-05	0.00029	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	7.24e-05	0.000289	CcSEcCtD
Aprepitant—Discomfort—Doxorubicin—pancreatic cancer	7.21e-05	0.000288	CcSEcCtD
Aprepitant—Anorexia—Epirubicin—pancreatic cancer	7.2e-05	0.000288	CcSEcCtD
Aprepitant—Dry mouth—Doxorubicin—pancreatic cancer	7.13e-05	0.000285	CcSEcCtD
Aprepitant—Vomiting—Docetaxel—pancreatic cancer	7.12e-05	0.000285	CcSEcCtD
Aprepitant—Rash—Docetaxel—pancreatic cancer	7.06e-05	0.000282	CcSEcCtD
Aprepitant—Hypotension—Epirubicin—pancreatic cancer	7.06e-05	0.000282	CcSEcCtD
Aprepitant—Dermatitis—Docetaxel—pancreatic cancer	7.06e-05	0.000282	CcSEcCtD
Aprepitant—Confusional state—Doxorubicin—pancreatic cancer	7.05e-05	0.000282	CcSEcCtD
Aprepitant—Headache—Docetaxel—pancreatic cancer	7.02e-05	0.00028	CcSEcCtD
Aprepitant—Anaphylactic shock—Doxorubicin—pancreatic cancer	6.99e-05	0.000279	CcSEcCtD
Aprepitant—Oedema—Doxorubicin—pancreatic cancer	6.99e-05	0.000279	CcSEcCtD
Aprepitant—Infection—Doxorubicin—pancreatic cancer	6.95e-05	0.000277	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—CCKAR—pancreatic cancer	6.93e-05	0.000568	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—pancreatic cancer	6.91e-05	0.000567	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	6.89e-05	0.000275	CcSEcCtD
Aprepitant—Shock—Doxorubicin—pancreatic cancer	6.88e-05	0.000275	CcSEcCtD
Aprepitant—Nervous system disorder—Doxorubicin—pancreatic cancer	6.86e-05	0.000274	CcSEcCtD
Aprepitant—Thrombocytopenia—Doxorubicin—pancreatic cancer	6.85e-05	0.000273	CcSEcCtD
Aprepitant—Insomnia—Epirubicin—pancreatic cancer	6.83e-05	0.000273	CcSEcCtD
Aprepitant—Tachycardia—Doxorubicin—pancreatic cancer	6.82e-05	0.000273	CcSEcCtD
Aprepitant—Skin disorder—Doxorubicin—pancreatic cancer	6.79e-05	0.000271	CcSEcCtD
Aprepitant—Paraesthesia—Epirubicin—pancreatic cancer	6.79e-05	0.000271	CcSEcCtD
Aprepitant—Hyperhidrosis—Doxorubicin—pancreatic cancer	6.76e-05	0.00027	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—HIF1A—pancreatic cancer	6.74e-05	0.000552	CbGpPWpGaD
Aprepitant—Dyspnoea—Epirubicin—pancreatic cancer	6.74e-05	0.000269	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—JAG2—pancreatic cancer	6.72e-05	0.000551	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TSC2—pancreatic cancer	6.72e-05	0.000551	CbGpPWpGaD
Aprepitant—Somnolence—Epirubicin—pancreatic cancer	6.72e-05	0.000268	CcSEcCtD
Aprepitant—Anorexia—Doxorubicin—pancreatic cancer	6.67e-05	0.000266	CcSEcCtD
Aprepitant—Nausea—Docetaxel—pancreatic cancer	6.65e-05	0.000266	CcSEcCtD
Aprepitant—Dyspepsia—Epirubicin—pancreatic cancer	6.65e-05	0.000266	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—MEN1—pancreatic cancer	6.63e-05	0.000543	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—APOE—pancreatic cancer	6.58e-05	0.000539	CbGpPWpGaD
Aprepitant—Decreased appetite—Epirubicin—pancreatic cancer	6.57e-05	0.000262	CcSEcCtD
Aprepitant—Hypotension—Doxorubicin—pancreatic cancer	6.53e-05	0.000261	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Epirubicin—pancreatic cancer	6.52e-05	0.000261	CcSEcCtD
Aprepitant—Fatigue—Epirubicin—pancreatic cancer	6.52e-05	0.00026	CcSEcCtD
Aprepitant—CYP1A2—Arachidonic acid metabolism—PTGS2—pancreatic cancer	6.47e-05	0.00053	CbGpPWpGaD
Aprepitant—Constipation—Epirubicin—pancreatic cancer	6.46e-05	0.000258	CcSEcCtD
Aprepitant—Pain—Epirubicin—pancreatic cancer	6.46e-05	0.000258	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—KDR—pancreatic cancer	6.45e-05	0.000528	CbGpPWpGaD
Aprepitant—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	6.37e-05	0.000254	CcSEcCtD
Aprepitant—Insomnia—Doxorubicin—pancreatic cancer	6.32e-05	0.000253	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—SHH—pancreatic cancer	6.32e-05	0.000518	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NOTCH4—pancreatic cancer	6.28e-05	0.000515	CbGpPWpGaD
Aprepitant—Paraesthesia—Doxorubicin—pancreatic cancer	6.28e-05	0.000251	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—IAPP—pancreatic cancer	6.24e-05	0.000512	CbGpPWpGaD
Aprepitant—Dyspnoea—Doxorubicin—pancreatic cancer	6.23e-05	0.000249	CcSEcCtD
Aprepitant—Feeling abnormal—Epirubicin—pancreatic cancer	6.23e-05	0.000249	CcSEcCtD
Aprepitant—Somnolence—Doxorubicin—pancreatic cancer	6.22e-05	0.000248	CcSEcCtD
Aprepitant—Gastrointestinal pain—Epirubicin—pancreatic cancer	6.18e-05	0.000247	CcSEcCtD
Aprepitant—Dyspepsia—Doxorubicin—pancreatic cancer	6.16e-05	0.000246	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—NFKBIA—pancreatic cancer	6.13e-05	0.000503	CbGpPWpGaD
Aprepitant—Decreased appetite—Doxorubicin—pancreatic cancer	6.08e-05	0.000243	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—NOTCH1—pancreatic cancer	6.07e-05	0.000498	CbGpPWpGaD
Aprepitant—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	6.04e-05	0.000241	CcSEcCtD
Aprepitant—Fatigue—Doxorubicin—pancreatic cancer	6.03e-05	0.000241	CcSEcCtD
Aprepitant—Urticaria—Epirubicin—pancreatic cancer	6e-05	0.00024	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—PTHLH—pancreatic cancer	5.99e-05	0.000491	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTCH1—pancreatic cancer	5.99e-05	0.000491	CbGpPWpGaD
Aprepitant—Constipation—Doxorubicin—pancreatic cancer	5.98e-05	0.000239	CcSEcCtD
Aprepitant—Pain—Doxorubicin—pancreatic cancer	5.98e-05	0.000239	CcSEcCtD
Aprepitant—Abdominal pain—Epirubicin—pancreatic cancer	5.97e-05	0.000239	CcSEcCtD
Aprepitant—Body temperature increased—Epirubicin—pancreatic cancer	5.97e-05	0.000239	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—PIK3CG—pancreatic cancer	5.94e-05	0.000487	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—NRAS—pancreatic cancer	5.94e-05	0.000487	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EGF—pancreatic cancer	5.87e-05	0.000481	CbGpPWpGaD
Aprepitant—Feeling abnormal—Doxorubicin—pancreatic cancer	5.76e-05	0.00023	CcSEcCtD
Aprepitant—Gastrointestinal pain—Doxorubicin—pancreatic cancer	5.72e-05	0.000228	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—SRC—pancreatic cancer	5.59e-05	0.000458	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	5.59e-05	0.000458	CbGpPWpGaD
Aprepitant—Hypersensitivity—Epirubicin—pancreatic cancer	5.57e-05	0.000222	CcSEcCtD
Aprepitant—Urticaria—Doxorubicin—pancreatic cancer	5.55e-05	0.000222	CcSEcCtD
Aprepitant—Abdominal pain—Doxorubicin—pancreatic cancer	5.53e-05	0.000221	CcSEcCtD
Aprepitant—Body temperature increased—Doxorubicin—pancreatic cancer	5.53e-05	0.000221	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—SST—pancreatic cancer	5.48e-05	0.000449	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—pancreatic cancer	5.44e-05	0.000446	CbGpPWpGaD
Aprepitant—Asthenia—Epirubicin—pancreatic cancer	5.42e-05	0.000217	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—EGFR—pancreatic cancer	5.41e-05	0.000443	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—PIK3CG—pancreatic cancer	5.41e-05	0.000443	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—pancreatic cancer	5.38e-05	0.000441	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—JAG1—pancreatic cancer	5.36e-05	0.00044	CbGpPWpGaD
Aprepitant—Pruritus—Epirubicin—pancreatic cancer	5.35e-05	0.000214	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—NOTCH3—pancreatic cancer	5.34e-05	0.000438	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PIK3CD—pancreatic cancer	5.22e-05	0.000428	CbGpPWpGaD
Aprepitant—Diarrhoea—Epirubicin—pancreatic cancer	5.17e-05	0.000207	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.17e-05	0.000424	CbGpPWpGaD
Aprepitant—Hypersensitivity—Doxorubicin—pancreatic cancer	5.15e-05	0.000206	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—KRAS—pancreatic cancer	5.11e-05	0.000419	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CNR1—pancreatic cancer	5.06e-05	0.000415	CbGpPWpGaD
Aprepitant—Asthenia—Doxorubicin—pancreatic cancer	5.02e-05	0.0002	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—MYC—pancreatic cancer	5.01e-05	0.000411	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	5e-05	0.00041	CbGpPWpGaD
Aprepitant—Dizziness—Epirubicin—pancreatic cancer	5e-05	0.0002	CcSEcCtD
Aprepitant—CYP3A7—Metabolism—PRSS1—pancreatic cancer	4.95e-05	0.000406	CbGpPWpGaD
Aprepitant—Pruritus—Doxorubicin—pancreatic cancer	4.95e-05	0.000198	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—PIK3CG—pancreatic cancer	4.91e-05	0.000402	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—pancreatic cancer	4.9e-05	0.000402	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	4.9e-05	0.000402	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—GCG—pancreatic cancer	4.88e-05	0.0004	CbGpPWpGaD
Aprepitant—Vomiting—Epirubicin—pancreatic cancer	4.8e-05	0.000192	CcSEcCtD
Aprepitant—Diarrhoea—Doxorubicin—pancreatic cancer	4.78e-05	0.000191	CcSEcCtD
Aprepitant—Rash—Epirubicin—pancreatic cancer	4.76e-05	0.00019	CcSEcCtD
Aprepitant—Dermatitis—Epirubicin—pancreatic cancer	4.76e-05	0.00019	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—PIK3CD—pancreatic cancer	4.75e-05	0.00039	CbGpPWpGaD
Aprepitant—Headache—Epirubicin—pancreatic cancer	4.73e-05	0.000189	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—PIK3CA—pancreatic cancer	4.69e-05	0.000385	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	4.67e-05	0.000383	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—pancreatic cancer	4.67e-05	0.000383	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AGTR1—pancreatic cancer	4.66e-05	0.000382	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—pancreatic cancer	4.63e-05	0.000379	CbGpPWpGaD
Aprepitant—Dizziness—Doxorubicin—pancreatic cancer	4.62e-05	0.000185	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—STK11—pancreatic cancer	4.59e-05	0.000376	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PIK3CB—pancreatic cancer	4.55e-05	0.000373	CbGpPWpGaD
Aprepitant—Nausea—Epirubicin—pancreatic cancer	4.49e-05	0.000179	CcSEcCtD
Aprepitant—Vomiting—Doxorubicin—pancreatic cancer	4.45e-05	0.000178	CcSEcCtD
Aprepitant—Rash—Doxorubicin—pancreatic cancer	4.41e-05	0.000176	CcSEcCtD
Aprepitant—Dermatitis—Doxorubicin—pancreatic cancer	4.4e-05	0.000176	CcSEcCtD
Aprepitant—Headache—Doxorubicin—pancreatic cancer	4.38e-05	0.000175	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—CXCL8—pancreatic cancer	4.37e-05	0.000358	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—HRAS—pancreatic cancer	4.34e-05	0.000356	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PIK3CD—pancreatic cancer	4.31e-05	0.000354	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ARG2—pancreatic cancer	4.29e-05	0.000352	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—AKT1—pancreatic cancer	4.22e-05	0.000346	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CASP3—pancreatic cancer	4.18e-05	0.000343	CbGpPWpGaD
Aprepitant—Nausea—Doxorubicin—pancreatic cancer	4.15e-05	0.000166	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—PIK3CB—pancreatic cancer	4.14e-05	0.00034	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CCND1—pancreatic cancer	4.07e-05	0.000334	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CTNNB1—pancreatic cancer	4.03e-05	0.000331	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SMAD4—pancreatic cancer	4.02e-05	0.00033	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL8—pancreatic cancer	3.98e-05	0.000326	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MMP9—pancreatic cancer	3.95e-05	0.000324	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—pancreatic cancer	3.93e-05	0.000323	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PTEN—pancreatic cancer	3.93e-05	0.000322	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HES1—pancreatic cancer	3.93e-05	0.000322	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—AKT1—pancreatic cancer	3.84e-05	0.000314	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PIK3CB—pancreatic cancer	3.76e-05	0.000308	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—TYMP—pancreatic cancer	3.75e-05	0.000308	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SRC—pancreatic cancer	3.65e-05	0.000299	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCL8—pancreatic cancer	3.61e-05	0.000296	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PRSS1—pancreatic cancer	3.58e-05	0.000293	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—VEGFA—pancreatic cancer	3.55e-05	0.000291	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—STAT3—pancreatic cancer	3.52e-05	0.000288	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—NRAS—pancreatic cancer	3.51e-05	0.000288	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TERT—pancreatic cancer	3.44e-05	0.000282	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HIF1A—pancreatic cancer	3.29e-05	0.00027	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TSC2—pancreatic cancer	3.28e-05	0.000269	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MYC—pancreatic cancer	3.27e-05	0.000268	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TGFB1—pancreatic cancer	3.26e-05	0.000267	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—APOE—pancreatic cancer	3.21e-05	0.000263	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EGFR—pancreatic cancer	3.2e-05	0.000262	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KDR—pancreatic cancer	3.15e-05	0.000258	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ARG2—pancreatic cancer	3.1e-05	0.000254	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GLP1R—pancreatic cancer	3.03e-05	0.000248	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—KRAS—pancreatic cancer	3.02e-05	0.000247	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NFKBIA—pancreatic cancer	2.99e-05	0.000245	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—DPYD—pancreatic cancer	2.98e-05	0.000244	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NOTCH1—pancreatic cancer	2.97e-05	0.000243	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CG—pancreatic cancer	2.9e-05	0.000238	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—NRAS—pancreatic cancer	2.9e-05	0.000238	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EGF—pancreatic cancer	2.87e-05	0.000235	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—SLC2A2—pancreatic cancer	2.82e-05	0.000232	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PIK3CA—pancreatic cancer	2.77e-05	0.000227	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PRSS1—pancreatic cancer	2.77e-05	0.000227	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TYMP—pancreatic cancer	2.71e-05	0.000222	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TP53—pancreatic cancer	2.68e-05	0.00022	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—EGFR—pancreatic cancer	2.64e-05	0.000217	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—HRAS—pancreatic cancer	2.57e-05	0.00021	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CD—pancreatic cancer	2.55e-05	0.000209	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.52e-05	0.000207	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PRSS1—pancreatic cancer	2.52e-05	0.000207	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—KRAS—pancreatic cancer	2.5e-05	0.000205	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ARG2—pancreatic cancer	2.4e-05	0.000197	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—PIK3CA—pancreatic cancer	2.29e-05	0.000188	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—AKT1—pancreatic cancer	2.27e-05	0.000186	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CB—pancreatic cancer	2.22e-05	0.000182	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ARG2—pancreatic cancer	2.19e-05	0.000179	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CD44—pancreatic cancer	2.19e-05	0.000179	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GLP1R—pancreatic cancer	2.19e-05	0.000179	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PRSS1—pancreatic cancer	2.16e-05	0.000177	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—DPYD—pancreatic cancer	2.15e-05	0.000176	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL8—pancreatic cancer	2.14e-05	0.000175	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—HRAS—pancreatic cancer	2.12e-05	0.000174	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TYMP—pancreatic cancer	2.1e-05	0.000172	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GCG—pancreatic cancer	2.1e-05	0.000172	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—AKT1—pancreatic cancer	2.06e-05	0.000169	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CASP3—pancreatic cancer	2.04e-05	0.000168	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SLC2A2—pancreatic cancer	2.04e-05	0.000167	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CCND1—pancreatic cancer	1.99e-05	0.000163	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—STK11—pancreatic cancer	1.97e-05	0.000162	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CTNNB1—pancreatic cancer	1.97e-05	0.000161	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MMP9—pancreatic cancer	1.93e-05	0.000158	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PTEN—pancreatic cancer	1.92e-05	0.000157	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TYMP—pancreatic cancer	1.91e-05	0.000157	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—AKT1—pancreatic cancer	1.87e-05	0.000154	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ARG2—pancreatic cancer	1.87e-05	0.000153	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SRC—pancreatic cancer	1.78e-05	0.000146	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—VEGFA—pancreatic cancer	1.73e-05	0.000142	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.73e-05	0.000142	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—STAT3—pancreatic cancer	1.72e-05	0.000141	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NRAS—pancreatic cancer	1.71e-05	0.00014	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—TYMS—pancreatic cancer	1.7e-05	0.000139	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GLP1R—pancreatic cancer	1.69e-05	0.000139	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PRSS1—pancreatic cancer	1.66e-05	0.000136	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—DPYD—pancreatic cancer	1.66e-05	0.000136	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TYMP—pancreatic cancer	1.63e-05	0.000134	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MYC—pancreatic cancer	1.6e-05	0.000131	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TGFB1—pancreatic cancer	1.59e-05	0.00013	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CD44—pancreatic cancer	1.58e-05	0.00013	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SLC2A2—pancreatic cancer	1.58e-05	0.000129	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.58e-05	0.000129	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.56e-05	0.000128	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EGFR—pancreatic cancer	1.56e-05	0.000128	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GLP1R—pancreatic cancer	1.54e-05	0.000126	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—DPYD—pancreatic cancer	1.52e-05	0.000124	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GCG—pancreatic cancer	1.52e-05	0.000124	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.51e-05	0.000124	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KRAS—pancreatic cancer	1.47e-05	0.000121	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ARG2—pancreatic cancer	1.44e-05	0.000118	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SLC2A2—pancreatic cancer	1.44e-05	0.000118	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—STK11—pancreatic cancer	1.43e-05	0.000117	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.42e-05	0.000117	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—APOE—pancreatic cancer	1.38e-05	0.000113	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.37e-05	0.000113	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.37e-05	0.000113	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CA—pancreatic cancer	1.35e-05	0.000111	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.35e-05	0.000111	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GLP1R—pancreatic cancer	1.32e-05	0.000108	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—pancreatic cancer	1.31e-05	0.000107	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—DPYD—pancreatic cancer	1.3e-05	0.000106	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TYMP—pancreatic cancer	1.26e-05	0.000103	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HRAS—pancreatic cancer	1.25e-05	0.000103	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.25e-05	0.000103	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CG—pancreatic cancer	1.24e-05	0.000102	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	1.23e-05	0.000101	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TYMS—pancreatic cancer	1.23e-05	0.0001	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CD44—pancreatic cancer	1.22e-05	0.0001	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.22e-05	9.98e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PPARG—pancreatic cancer	1.2e-05	9.85e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.2e-05	9.81e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.19e-05	9.72e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.17e-05	9.63e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GCG—pancreatic cancer	1.17e-05	9.61e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CD44—pancreatic cancer	1.11e-05	9.14e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AKT1—pancreatic cancer	1.11e-05	9.07e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—STK11—pancreatic cancer	1.1e-05	9.03e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CD—pancreatic cancer	1.09e-05	8.97e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.09e-05	8.95e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.08e-05	8.86e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.07e-05	8.77e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GCG—pancreatic cancer	1.07e-05	8.76e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.03e-05	8.48e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.02e-05	8.33e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—STK11—pancreatic cancer	1e-05	8.24e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—DPYD—pancreatic cancer	1e-05	8.2e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—APOE—pancreatic cancer	9.97e-06	8.17e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CB—pancreatic cancer	9.54e-06	7.82e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CD44—pancreatic cancer	9.52e-06	7.81e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	9.49e-06	7.78e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TYMS—pancreatic cancer	9.48e-06	7.77e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTGS2—pancreatic cancer	9.45e-06	7.75e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	9.43e-06	7.73e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	9.33e-06	7.65e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	9.24e-06	7.58e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GCG—pancreatic cancer	9.13e-06	7.49e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	9e-06	7.38e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PPARG—pancreatic cancer	8.69e-06	7.12e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TYMS—pancreatic cancer	8.64e-06	7.08e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—STK11—pancreatic cancer	8.59e-06	7.04e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTEN—pancreatic cancer	8.24e-06	6.76e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.06e-06	6.61e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	7.91e-06	6.48e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—APOE—pancreatic cancer	7.71e-06	6.32e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TYMS—pancreatic cancer	7.39e-06	6.05e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CD44—pancreatic cancer	7.35e-06	6.03e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	7.3e-06	5.98e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GCG—pancreatic cancer	7.05e-06	5.78e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—APOE—pancreatic cancer	7.03e-06	5.76e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CG—pancreatic cancer	6.96e-06	5.7e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	6.9e-06	5.65e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTGS2—pancreatic cancer	6.83e-06	5.6e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PPARG—pancreatic cancer	6.71e-06	5.5e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.65e-06	5.45e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—STK11—pancreatic cancer	6.63e-06	5.43e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CG—pancreatic cancer	6.34e-06	5.2e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PPARG—pancreatic cancer	6.12e-06	5.02e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CD—pancreatic cancer	6.12e-06	5.01e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—APOE—pancreatic cancer	6.01e-06	4.92e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTEN—pancreatic cancer	5.96e-06	4.88e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	5.82e-06	4.77e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TYMS—pancreatic cancer	5.7e-06	4.67e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.69e-06	4.66e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CD—pancreatic cancer	5.58e-06	4.57e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	5.42e-06	4.44e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CB—pancreatic cancer	5.33e-06	4.37e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTGS2—pancreatic cancer	5.28e-06	4.33e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PPARG—pancreatic cancer	5.23e-06	4.29e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CB—pancreatic cancer	4.86e-06	3.98e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTGS2—pancreatic cancer	4.82e-06	3.95e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	4.77e-06	3.91e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AKT1—pancreatic cancer	4.75e-06	3.89e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—APOE—pancreatic cancer	4.64e-06	3.8e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTEN—pancreatic cancer	4.61e-06	3.78e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	4.2e-06	3.45e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTEN—pancreatic cancer	4.2e-06	3.44e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	4.18e-06	3.43e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	4.15e-06	3.4e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTGS2—pancreatic cancer	4.12e-06	3.37e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PPARG—pancreatic cancer	4.04e-06	3.31e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	3.68e-06	3.01e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTEN—pancreatic cancer	3.59e-06	2.94e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AKT1—pancreatic cancer	3.43e-06	2.81e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CA—pancreatic cancer	3.25e-06	2.66e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	3.21e-06	2.63e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTGS2—pancreatic cancer	3.18e-06	2.6e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CA—pancreatic cancer	2.96e-06	2.43e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.77e-06	2.27e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AKT1—pancreatic cancer	2.65e-06	2.18e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	2.53e-06	2.08e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AKT1—pancreatic cancer	2.42e-06	1.98e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AKT1—pancreatic cancer	2.07e-06	1.7e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.95e-06	1.6e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.6e-06	1.31e-05	CbGpPWpGaD
